Stock Details
TAK is Takeda Pharmaceutical Company Limited's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 15.50$. Average daily volumn in 3 months 2.84M. Market cap 50.31B



Stock symbol : TAK. Exchange : NYSE. Currency : USD
Lastest price : 16.12$. Total volume : 2.32M. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

Takeda Pharmaceutical Company Limited (TAK)
Last Price
16.12$
Change
0.20
Volume
2.32M

Previous Close15.92
Open16.10
Day Range16.08-16.17
Bid16.10 x 4k
Ask16.12 x 2.9k
Volume2.32M
Average Volume2.84M
Market Cap50.31B
Beta0.70
52 Week Range12.28-16.30
Trailing P/E24.42
Foward P/E8.14
Dividend (Yield %)4.14%
Ex-Dividend Date2022-09-29



Financial Details


According to Takeda Pharmaceutical Company Limited's financial reports the company's revenue in 2022 were 3.57T an increase(0%) over the years 2021 revenue that were of 3.2T. In 2022 the company's total earnings were 230.06B while total earnings in 2021 were 376B(-38.83%).


Loading ...



Organization

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynov... ate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Market Cap:
50.31B
Revenue:
3.57T
Total Assets:
13.18T
Total Cash:
849.7B


News about "Takeda Pharmaceutical Company Limited"

takeda-completes-acquisition-of-nimbus-therapeutics-tyk2-program-subsidiary-image

Takeda Completes Acquisition of Nimbus Therapeuticsโ€™ TYK2 Program Subsidiary

Source from : YAHOO!Finance - 10 hours ago

Takeda today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. from Nimbus Therapeutics, LLC ...See details»


Takeda Pharmaceutical Co. Ltd.

Source from : Wall Street Journal - 20 days ago

1 Day TKPHF 2.43% DJIA 1.00% S&P 500 1.89% Health Care/Life Sciences 0.41% Christophe Weber President, CEO & Representative Director Takeda Pharmaceutical Co., Ltd. Constantine Saroukos Chief ...See details»


Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2023 Earnings Call Transcript

Source from : YAHOO!Finance - 5 days ago

Q3 2023 Earnings Call February 2, 2023 Christopher Oโ€™Reilly: Thank you for taking time out of your very busy schedule to join us for the FY ย€ย˜22 Q3 Earnings Announcement by Takeda. My name is Oโ€™Reilly ...See details»


why-takeda-pharmaceutical-company-limited-taks-most-recent-report-reveals-some-hints-about-its-future-image

Why Takeda Pharmaceutical Company Limited (TAK)โ€™s Most Recent Report Reveals Some Hints About Its Future

Source from : newsheater - 2 years ago

Takeda Pharmaceutical Company Limited (NYSE:TAK) went down by -0.43% from its latest closing price compared to the recent 1-year high of $16.30. The companyโ€™s stock price has collected -1.48% of loss ...See details»


Takeda Pharmaceutical Company Limited: When The Timing Is Right, Sit Tight

Source from : stocksregister - 4 days ago

Takeda Pharmaceutical Company Limited (NYSE:TAK) price on Friday, February 03, rose 1.46% above its previous dayโ€™s close as an upside momentum from buyers pushed the stockโ€™s value to $15.97. A look at ...See details»


Takeda Pharmaceutical Company Limited (NYSE: TAK) Up 1.8% This Year: What Should You Expect Next?

Source from : stocksregister - 5 month ago

Takeda Pharmaceutical Company Limited (NYSE:TAK) price is hovering lower on Wednesday, February 01, dropping -0.60% below its previous close. A look at todayโ€™s price movement shows that the recent ...See details»


Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Source from : Nasdaq - 2 years ago

The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces the ...See details»


Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMEDโ€™s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

Source from : newsroom.businesswire.com - 17 days ago

About Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan ...See details»


Takeda Pharmaceutical Company (TAK) Presents At 41st Annual Healthcare Conference - Slideshow

Source from : Seeking Alpha - 20 days ago

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site ...See details»


Takeda Pharmaceutical Company Limited (4502.T)

Source from : Yahoo Finance - 7 days ago

1 Prior to todayโ€™s approval, the only approved routine prophylaxis treatment options for children 6 to <12 years of age requir Japan's Takeda Pharmaceutical Co posted a 13% drop in operating earnings ...See details»


Takeda'S Exkivity Gets Approval In China For Metastatic Lung Cancer After Chemo

Source from : Business Insider - 28 days ago

(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TKPHF.PK, TAK ... has progressed on or after platinum-based chemotherapy. The company said the approval is based on the Phase 1/2 trial and has shown ...See details»


Takeda Pharmaceutical Company Limited (TAK)

Source from : Yahoo Finance - 2 years ago

Up Last 7 Days N/A N/A N/A N/A Up Last 30 Days N/A N/A N/A N/A Down Last 7 Days N/A N/A N/A N/A Down Last 30 Days N/A N/A N/A N/A ...See details»


Takeda Pharmaceutical Stock (NYSE:TAK), Dividends

Source from : Benzinga.com - 8 month ago

Takeda Pharmaceutical issues dividends to shareholders from excess cash Takeda Pharmaceutical generates. Most companies pay dividends on a quarterly basis, but dividends may also be paid monthly ...See details»


Takeda Pharmaceutical Co Ltd

Source from : Reuters - 2 years ago

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of ...See details»